Plain-English translation of NCT06636552 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination of medications including daratumumab (a type of immunotherapy drug) plus alternating chemotherapy regimens can help people with a rare blood cancer called primary plasma cell leukemia. If the initial treatment works well, participants may receive a stem cell transplant and then continue the medication as maintenance therapy for up to two years.
Primary plasma cell leukemia is a very aggressive form of blood cancer with limited treatment options. This trial aims to find out whether combining this medication with chemotherapy can improve outcomes for patients who are newly diagnosed and strong enough to handle intensive treatment.
You likely qualify if…
You likely don't qualify if…
You would start with six three-week cycles of alternating chemotherapy combinations given with daratumumab. Depending on how well you respond, you may then receive a stem cell transplant (if eligible), followed by two more three-week cycles of chemotherapy. If your cancer responds well, you would then receive maintenance therapy with daratumumab alone for up to two years, given as monthly infusions. Throughout the trial, you would have regular clinic visits for blood tests, scans, and disease monitoring.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Greece